Core sleep growth offsets ventilator suspension and software shift
- Core sleep device sales grew 9 percent globally in Q4 FY26.
- The company will divest its MatrixCare software business to refocus on faster growing software segments.
- New sales of Astral ventilators are suspended for fiscal 2027 due to a field safety action.
- GLP-1 drugs look more like a demand tailwind than a threat based on company adherence data.
- Noctrix adds a new RLS therapy but reimbursement and integration are still open questions.
Strong core, shifting edges
ResMed is executing well in its main sleep and breathing business. In Q4 FY26, global sleep device sales grew 9 percent, and gross margins expanded 90 basis points year over year. The core sleep apnea market remains healthy, driven by volume growth and increased sleep health awareness.
Management took decisive actions on two fronts this quarter. They announced the divestiture of the underperforming MatrixCare software business, which removes a drag on the Residential Care Software segment. They also suspended new sales of Astral ventilators for fiscal 2027 to focus on a field safety action, creating an estimated $75 million revenue headwind.
The broader bull case relies on GLP-1 weight loss drugs remaining a net benefit for CPAP adherence. ResMed also continues to integrate its Noctrix Health acquisition to treat Restless Legs Syndrome, opening a new growth channel if it can scale effectively through existing sales teams.
The bear case focuses on near-term distractions. The Astral recall requires management attention and takes a bite out of top-line growth. Meanwhile, inflation in electronic components and freight requires constant supply chain optimization to protect margins. Investors will watch the execution of the software divestiture and the ventilator safety action closely.
Devices start it, masks repeat it
ResMed makes money by selling sleep apnea and breathing devices, masks, accessories, and software. Its CPAP and bilevel machines help keep a patient airway open during sleep. The company sells through distributors, home healthcare dealers, and directly to patients in some markets.
The model works because a device sale often starts a longer relationship. Patients need masks, cushions, tubes, and filters over time. Cloud tools such as AirView for clinicians and myAir for patients help track use and make the ecosystem stickier.
Residential Care Software is a smaller recurring revenue segment. ResMed is divesting MatrixCare, a long-term care product, to focus on its Brightree and MEDIFOX DAN platforms for home medical equipment and out-of-hospital care.
Recent deals push ResMed deeper into the patient journey. VirtuOx gives it home-based diagnostic testing. Noctrix gives it a therapy for Restless Legs Syndrome. Both expand the sleep health platform but add new billing and regulatory work.
What ResMed sells
AirSense and AirCurve devices
These connected flow generators treat sleep apnea by pushing air through a mask. Devices remain the biggest product line inside Sleep and Breathing Health.
Astral ventilators
Life support ventilators that are currently facing a field safety action, with new sales temporarily suspended for all of fiscal 2027.
Masks and accessories
Masks, cushions, and related supplies are repeat-use products. These generate high margin recurring revenue as patients replace worn parts.
Residential Care Software
Brightree and MEDIFOX DAN support home medical equipment providers and other care settings. The MatrixCare business is being divested.
VirtuOx diagnostics
VirtuOx adds home-based diagnostic testing for sleep, respiratory, cardiac, and other conditions.
NIDRA for Restless Legs Syndrome
NIDRA came through the Noctrix Health deal. It is a non-invasive nerve stimulation device for moderate to severe Restless Legs Syndrome.
Two reported engines
Mix is based on net revenue for the three months ended March 31, 2026. Sleep and Breathing Health produced about 88 percent of revenue, showing ResMed remains primarily a device and mask company.
What could break the thesis
Astral ventilator suspension
High impact · High oddsResMed suspended new sales of its Astral ventilators for fiscal 2027 to address a field safety action. This creates an estimated $75 million revenue headwind and required a $42 million provision in Q4 FY26.
MatrixCare divestiture
Medium impact · Medium oddsThe company expects to close the sale of MatrixCare around September 1, 2026. If the remaining software business fails to hit the promised high single-digit growth target, investors may question the software strategy.
Component and freight inflation
High impact · Medium oddsResMed has expanded gross margins recently through manufacturing and logistics efficiencies. However, persistent inflation in electronic components and freight costs could pressure earnings if price increases or productivity gains slow down.
Philips returns to the market
Medium impact · Medium oddsPhilips competes in many non-U.S. markets, and a fuller U.S. return would add pressure. Fisher & Paykel and other makers also fight for share. Any slowdown in mask growth would hurt repeat revenue.
Reimbursement or regulation shifts
High impact · Medium oddsSleep apnea care depends on Medicare and private insurers covering devices and diagnostics. Tighter coverage rules could hurt volumes. VirtuOx and Noctrix also add more direct healthcare oversight.
In one breath
What does ResMed actually do?
ResMed sells devices, masks, and software used to diagnose, treat, and manage sleep apnea and other breathing problems. Its main products help people breathe during sleep and help care teams track whether therapy is working.
Are GLP-1 weight loss drugs bad for ResMed?
The current company view is that they are more likely a tailwind than a threat. ResMed says PAP patients who later start GLP-1 therapy had higher resupply rates at three years than PAP-only patients.
What is happening with the software business?
ResMed is selling its underperforming MatrixCare long-term care software business. It expects the remaining software units, like Brightree, to return to high single-digit revenue growth.
Why are Astral ventilator sales suspended?
ResMed is executing a field safety corrective action for the devices. New sales are suspended for all of fiscal 2027 to focus on supporting existing patients, creating a revenue headwind.
